➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Boehringer Ingelheim
Mallinckrodt
Baxter
Harvard Business School

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AIR POLYMER-TYPE A

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Air Polymer-type A

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT04026945 Sustained Release Lidocaine for Treatment of Scrotal Pain Not yet recruiting University of British Columbia Phase 1/Phase 2 2019-07-01 In this study, we are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Air Polymer-type A

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003876 Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma Completed Barrett Cancer Center Phase 1 1999-04-01 RATIONALE: Internal radiation uses high-energy radiation to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining internal radiation therapy with chemotherapy implants may kill remaining tumor cells following surgery. PURPOSE: Phase I trial to study the effectiveness of internal radiation therapy plus carmustine implants in treating patients who have recurrent or refractory malignant glioma.
NCT00003878 Carmustine Implants in Treating Patients With Brain Metastases Completed National Cancer Institute (NCI) Phase 2 2002-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.
NCT00003878 Carmustine Implants in Treating Patients With Brain Metastases Completed New Approaches to Brain Tumor Therapy Consortium Phase 2 2002-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Air Polymer-type A

Condition Name

Condition Name for Air Polymer-type A
Intervention Trials
Coronary Artery Disease 6
Acute Coronary Syndrome 4
Metastatic Breast Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Air Polymer-type A
Intervention Trials
Coronary Artery Disease 9
Myocardial Ischemia 8
Coronary Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Air Polymer-type A

Trials by Country

Trials by Country for Air Polymer-type A
Location Trials
United States 116
Canada 15
Korea, Republic of 8
Russian Federation 6
Thailand 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Air Polymer-type A
Location Trials
California 12
Florida 8
Maryland 8
Ohio 7
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Air Polymer-type A

Clinical Trial Phase

Clinical Trial Phase for Air Polymer-type A
Clinical Trial Phase Trials
Phase 4 16
Phase 3 10
Phase 2 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Air Polymer-type A
Clinical Trial Phase Trials
Completed 38
Recruiting 22
Not yet recruiting 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Air Polymer-type A

Sponsor Name

Sponsor Name for Air Polymer-type A
Sponsor Trials
National Cancer Institute (NCI) 9
Meabco A/S 5
Norwegian University of Life Sciences 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Air Polymer-type A
Sponsor Trials
Other 101
Industry 54
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
McKinsey
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.